S&P 500   4,564.67 (-0.11%)
DOW   36,123.24 (-0.22%)
QQQ   386.33 (+0.00%)
AAPL   192.98 (+1.87%)
MSFT   371.88 (+0.74%)
META   316.87 (-0.98%)
GOOGL   130.52 (+0.97%)
AMZN   146.78 (+1.34%)
TSLA   238.48 (+1.23%)
NVDA   462.63 (+1.65%)
NIO   7.53 (+2.87%)
BABA   72.42 (-0.84%)
AMD   118.09 (-0.40%)
T   17.24 (+3.48%)
F   10.62 (-0.75%)
MU   73.62 (-0.90%)
CGC   0.66 (-12.29%)
GE   120.74 (-0.65%)
DIS   90.50 (-1.64%)
AMC   7.03 (-6.14%)
PFE   29.18 (-0.34%)
PYPL   57.57 (-3.81%)
XOM   100.97 (-1.43%)
S&P 500   4,564.67 (-0.11%)
DOW   36,123.24 (-0.22%)
QQQ   386.33 (+0.00%)
AAPL   192.98 (+1.87%)
MSFT   371.88 (+0.74%)
META   316.87 (-0.98%)
GOOGL   130.52 (+0.97%)
AMZN   146.78 (+1.34%)
TSLA   238.48 (+1.23%)
NVDA   462.63 (+1.65%)
NIO   7.53 (+2.87%)
BABA   72.42 (-0.84%)
AMD   118.09 (-0.40%)
T   17.24 (+3.48%)
F   10.62 (-0.75%)
MU   73.62 (-0.90%)
CGC   0.66 (-12.29%)
GE   120.74 (-0.65%)
DIS   90.50 (-1.64%)
AMC   7.03 (-6.14%)
PFE   29.18 (-0.34%)
PYPL   57.57 (-3.81%)
XOM   100.97 (-1.43%)
S&P 500   4,564.67 (-0.11%)
DOW   36,123.24 (-0.22%)
QQQ   386.33 (+0.00%)
AAPL   192.98 (+1.87%)
MSFT   371.88 (+0.74%)
META   316.87 (-0.98%)
GOOGL   130.52 (+0.97%)
AMZN   146.78 (+1.34%)
TSLA   238.48 (+1.23%)
NVDA   462.63 (+1.65%)
NIO   7.53 (+2.87%)
BABA   72.42 (-0.84%)
AMD   118.09 (-0.40%)
T   17.24 (+3.48%)
F   10.62 (-0.75%)
MU   73.62 (-0.90%)
CGC   0.66 (-12.29%)
GE   120.74 (-0.65%)
DIS   90.50 (-1.64%)
AMC   7.03 (-6.14%)
PFE   29.18 (-0.34%)
PYPL   57.57 (-3.81%)
XOM   100.97 (-1.43%)
S&P 500   4,564.67 (-0.11%)
DOW   36,123.24 (-0.22%)
QQQ   386.33 (+0.00%)
AAPL   192.98 (+1.87%)
MSFT   371.88 (+0.74%)
META   316.87 (-0.98%)
GOOGL   130.52 (+0.97%)
AMZN   146.78 (+1.34%)
TSLA   238.48 (+1.23%)
NVDA   462.63 (+1.65%)
NIO   7.53 (+2.87%)
BABA   72.42 (-0.84%)
AMD   118.09 (-0.40%)
T   17.24 (+3.48%)
F   10.62 (-0.75%)
MU   73.62 (-0.90%)
CGC   0.66 (-12.29%)
GE   120.74 (-0.65%)
DIS   90.50 (-1.64%)
AMC   7.03 (-6.14%)
PFE   29.18 (-0.34%)
PYPL   57.57 (-3.81%)
XOM   100.97 (-1.43%)

Immunovant Stock Price, News & Analysis (NASDAQ:IMVT)

$40.40
-0.41 (-1.00%)
(As of 01:57 PM ET)
Compare
Today's Range
$39.75
$40.84
50-Day Range
$31.31
$40.81
52-Week Range
$14.05
$44.19
Volume
395,031 shs
Average Volume
1.39 million shs
Market Capitalization
$5.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.62

Immunovant MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5.3% Upside
$42.62 Price Target
Short Interest
Bearish
11.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Immunovant in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$58 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.82) to ($1.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

844th out of 949 stocks

Biological Products, Except Diagnostic Industry

139th out of 152 stocks


IMVT stock logo

About Immunovant Stock (NASDAQ:IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Stock Price History

IMVT Stock News Headlines

Immunovant, Inc. (NASDAQ:IMVT) Short Interest Update
UBS Group Raises Immunovant (NASDAQ:IMVT) Price Target to $56.00
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Analyst Ratings for Immunovant
Here’s Why Immunovant (IMVT) Outperformed in Q3
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Immunovant, Inc. (NASDAQ:IMVT) CEO Sells $531,593.26 in Stock
Immunovant Inc CEO Peter Salzmann Sells Over 16,000 Shares
Where Immunovant Stands With Analysts
Immunovant to Present at Upcoming Investor Conferences
Recap: Immunovant Q2 Earnings
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/05/2023
Next Earnings (Estimated)
2/02/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.62
High Stock Price Target
$57.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+4.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.78 per share

Miscellaneous

Free Float
137,718,000
Market Cap
$5.90 billion
Optionable
Not Optionable
Beta
0.70
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives















IMVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price target for 2024?

13 brokers have issued 1-year price targets for Immunovant's stock. Their IMVT share price targets range from $21.00 to $57.00. On average, they predict the company's stock price to reach $42.62 in the next year. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2023?

Immunovant's stock was trading at $17.75 on January 1st, 2023. Since then, IMVT stock has increased by 127.9% and is now trading at $40.46.
View the best growth stocks for 2023 here
.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,060,000 shares, an increase of 5.5% from the October 31st total of 6,690,000 shares. Based on an average daily volume of 2,150,000 shares, the short-interest ratio is currently 3.3 days. Currently, 11.6% of the shares of the stock are sold short.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45).

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Who are Immunovant's major shareholders?

Immunovant's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (5.36%), Alpine Global Management LLC (0.87%), Fred Alger Management LLC (0.82%), Avidity Partners Management LP (0.81%), Redmile Group LLC (0.76%) and Armistice Capital LLC (0.72%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends
.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IMVT) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -